Ptcy
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 5 | 12 | 3 | 1 | — | 18 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | 3 | — | 1 | 1 | 5 |
| Myeloid sarcoma | D023981 | — | C92.3 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 5 | 19 | 4 | — | 3 | 28 |
| Myelodysplastic syndromes | D009190 | — | D46 | 4 | 16 | 4 | — | — | 21 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 13 | 3 | — | 2 | 19 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 3 | 9 | 2 | — | 1 | 14 |
| Preleukemia | D011289 | — | — | — | 11 | 2 | — | — | 13 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 9 | 1 | — | 1 | 12 |
| Lymphoma | D008223 | — | C85.9 | 3 | 10 | 1 | — | — | 12 |
| Hematologic neoplasms | D019337 | — | — | 4 | 6 | 1 | — | 1 | 10 |
| Syndrome | D013577 | — | — | — | 9 | 1 | — | — | 10 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 6 | 1 | — | — | 8 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 2 | 9 | — | — | — | 9 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 6 | — | — | — | 7 |
| Lymphoid leukemia | D007945 | — | C91 | — | 5 | — | — | 1 | 6 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 4 | — | — | — | 5 |
| Hodgkin disease | D006689 | — | C81 | 2 | 4 | — | — | — | 5 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 4 | — | — | — | 4 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | 4 | — | — | — | 4 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 2 | — | — | — | 3 |
| Immune system diseases | D007154 | — | D89.9 | — | 3 | — | — | — | 3 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 3 | — | — | — | 3 |
Show 46 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | 1 | — | — | — | — | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | 1 | — | — | — | — | 1 |
| Sclerosis | D012598 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stem cell transplantation | D033581 | — | — | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | — |
| INN | — |
| Description | — |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | — |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use